Skip to main content
Erschienen in: Clinical Drug Investigation 2/2011

01.02.2011 | Oriinal Research Article

Assessment of the Potential for Displacement Interactions with Sugammadex

A Pharmacokinetic-Pharmacodynamic Modelling Approach

verfasst von: Mr Alex Zwiers, Michiel van den Heuve, Jean Smeets, Samantha Rutherford

Erschienen in: Clinical Drug Investigation | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background: Sugammadex is a γ-cyclodextrin that binds with high affinity to the neuromuscular blocking agents (NMBAs) rocuronium (bromide) and vecuronium (bromide) by encapsulation. Cyclodextrins are known to form inclusion complexes with other compounds.
Objectives: We utilized a previously developed pharmacokinetic-pharmaco-dynamic model to identify potential clinically relevant displacement interactions with sugammadex. The potential for sugammadex to capture other drug molecules, thereby reducing their efficacy, is not discussed here.
Methods: Isothermal titration calorimetry (ITC) was used to determine the binding affinity (estimated by association rate constant [kass]) between sugammadex and 300 commonly prescribed drugs. The screening included drugs commonly used in or shortly after anaesthesia, commonly prescribed drugs such as antidepressants and cardiovascular drugs, drugs (both steroidal and nonsteroidal) acting on steroidal receptors (such as the corticosteroids hydrocortisone, prednisolone and dexamethasone), and the selective estrogen receptor modulator toremifene. The model took into account the population pharmacokinetic-pharmacodynamic relationships of sugammadex, rocuronium and vecuronium, the binding affinities of the NMBAs and other compounds as determined by ITC, and the relationship between the free concentration of NMBA with sugammadex in the presence of a third complexed compound. Using the model, the critical concentrations of a con-comitantly administered compound required to result in a train-of-four (TOF) ratio of <0.9, indicating reoccurrence of neuromuscular blockade, for each plasma concentration of sugammadex and NMBA were calculated. For compounds with a kass value of ≥2.5 ×104 mol/L likely to be administered during sugammadex reversal, the combinations of kass and maximum plasma drug concentration (Cmax) were entered into a graph, consisting of a critical line established using a conservative approach, and those compounds above this critical line potentially resulting in a TOF ratio <0.9 were subsequently identified. Clinical validation was performed in a post hoc analysis of data from ten sugammadex studies, in which the impact of various drugs administered perioperatively on neuromuscular recovery was assessed for up to 1 hour after sugammadex administration.
Results: ITC analysis demonstrated that the binding affinity of rocuronium and vecuronium for sugammadex was very high, with kass values of 1.79 × 107 mol/L and 5.72 × 106 mol/L, respectively. Only three compounds (flucloxacillin, fusidic acid and toremifene) were found to have critical combinations of kass and Cmax, and thus the potential for displacement. Sugammadex was administered to 600 patients for reversal of rocuronium- or vecuronium-induced blockade in the ten analysed studies, in which 21 co-administered drugs were selected for analysis. No reoccurrence of blockade occurred in any patient.
Conclusion: Of 300 drugs screened, only three (flucloxacillin, fusidic acid and toremifene) were found to have potential for a displacement interaction with sugammadex, which might potentially be noticed as a delay in recovery of the TOF ratio to 0.9. A clinical study found no evidence of a clinically relevant displacement interaction of flucloxacillin with sugammadex; these findings confirm the highly conservative nature of the modelling and simulation assumptions in the present study.
Literatur
1.
Zurück zum Zitat Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002 Jan 18; 41(2): 266–70PubMedCrossRef Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002 Jan 18; 41(2): 266–70PubMedCrossRef
2.
Zurück zum Zitat Bom A, Epemolu O, Hope F, et al. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 2007 Jun; 7(3): 298–302PubMedCrossRef Bom A, Epemolu O, Hope F, et al. Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 2007 Jun; 7(3): 298–302PubMedCrossRef
3.
Zurück zum Zitat Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003 Sept; 99(3): 632–7PubMedCrossRef Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003 Sept; 99(3): 632–7PubMedCrossRef
4.
Zurück zum Zitat Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005 Oct; 103(4): 695–703PubMedCrossRef Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005 Oct; 103(4): 695–703PubMedCrossRef
5.
Zurück zum Zitat Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006 Aug; 97(2): 123–6PubMedCrossRef Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006 Aug; 97(2): 123–6PubMedCrossRef
6.
Zurück zum Zitat Ploeger BA, Smeets J, Strougo A, et al. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009 Jan; 110(1): 95–105PubMedCrossRef Ploeger BA, Smeets J, Strougo A, et al. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009 Jan; 110(1): 95–105PubMedCrossRef
7.
Zurück zum Zitat Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006 Jan; 96(1): 36–43PubMedCrossRef Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006 Jan; 96(1): 36–43PubMedCrossRef
8.
Zurück zum Zitat Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006 Apr; 104(4): 667–74PubMedCrossRef Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006 Apr; 104(4): 667–74PubMedCrossRef
9.
Zurück zum Zitat de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007 Aug; 107(2): 239–44PubMedCrossRef de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007 Aug; 107(2): 239–44PubMedCrossRef
10.
Zurück zum Zitat Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007 Mar; 104(3): 555–62PubMedCrossRef Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007 Mar; 104(3): 555–62PubMedCrossRef
11.
Zurück zum Zitat Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007 May; 106(5): 935–43PubMedCrossRef Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007 May; 106(5): 935–43PubMedCrossRef
12.
Zurück zum Zitat Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007 Feb; 106(2): 283–8PubMedCrossRef Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007 Feb; 106(2): 283–8PubMedCrossRef
13.
Zurück zum Zitat Vanacker BF, Vermeyen KM, Struys MM, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007 Mar; 104(3): 563–8PubMedCrossRef Vanacker BF, Vermeyen KM, Struys MM, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007 Mar; 104(3): 563–8PubMedCrossRef
14.
Zurück zum Zitat Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008 Aug; 109(2): 188–97PubMedCrossRef Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008 Aug; 109(2): 188–97PubMedCrossRef
15.
Zurück zum Zitat Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008 Oct; 101(4): 492–7PubMedCrossRef Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008 Oct; 101(4): 492–7PubMedCrossRef
16.
Zurück zum Zitat Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009 Feb; 110(2): 284–94PubMed Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009 Feb; 110(2): 284–94PubMed
17.
Zurück zum Zitat de Kam P-J, Cavens L, van den Heuvel M, et al. Flucloxacillin and diclofenac do not cause reoccurrence of blockade after reversal with sugammadex [abstract]. Anesthesiology 2009; A429 de Kam P-J, Cavens L, van den Heuvel M, et al. Flucloxacillin and diclofenac do not cause reoccurrence of blockade after reversal with sugammadex [abstract]. Anesthesiology 2009; A429
18.
Zurück zum Zitat Peeters P, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and primarily in an unchanged form via renal excretion [abstract]. Clin Pharmacol Ther 2009 Feb; 85Suppl 1: S83–4 Peeters P, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and primarily in an unchanged form via renal excretion [abstract]. Clin Pharmacol Ther 2009 Feb; 85Suppl 1: S83–4
Metadaten
Titel
Assessment of the Potential for Displacement Interactions with Sugammadex
A Pharmacokinetic-Pharmacodynamic Modelling Approach
verfasst von
Mr Alex Zwiers
Michiel van den Heuve
Jean Smeets
Samantha Rutherford
Publikationsdatum
01.02.2011
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 2/2011
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/BF03256937

Weitere Artikel der Ausgabe 2/2011

Clinical Drug Investigation 2/2011 Zur Ausgabe